We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+25.8%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$168M
AUM Growth
+$82.6M
Cap. Flow
+$37.9M
Cap. Flow %
22.57%
Top 10 Hldgs %
72.94%
Holding
26
New
7
Increased
6
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$16.3M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$8.86M
3
SLNO
Soleno Therapeutics
SLNO
+$8.82M
4
CBAY
Cymabay Therapeutics
CBAY
+$8.73M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$4.96M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$6.58M
2
ARDX icon
Ardelyx
ARDX
+$3.6M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.06M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.04M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$1.94M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-70,283
Closed -$3.06M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q4 2023 Portfolio in Review

As of Q4 2023, Ally Bridge Group held 26 positions worth $168M, up 97% from $85.2M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Ally Bridge Group deployed $37.9M of net new capital in Q4 2023, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was argenx: 35,000 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was MoonLake Immunotherapeutics, an estimated $2.04M trimmed.

  • Ally Bridge Group's largest Q4 2023 buy was argenx: 35,000 shares worth $13.3M.
  • Ally Bridge Group added most to Geron in Q4 2023, an estimated $1.46M increase.
  • Ally Bridge Group's biggest Q4 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $2.04M.
  • Ally Bridge Group fully exited Cytokinetics in Q4 2023, selling an estimated $6.58M.
  • Ally Bridge Group's ten largest holdings make up 73% of its $168M portfolio in Q4 2023.
  • Ally Bridge Group opened 7 new positions and closed 4 in Q4 2023.
  • Ally Bridge Group's portfolio value rose 97% quarter-over-quarter to $168M.

Based on Ally Bridge Group's 13F filing for Q4 2023, filed 14 Feb 2024.